We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
PURPOSE To compare single-agent pemetrexed ( P ) versus the combination of carboplatin and pemetrexed ( CP ) in first-line therapy for patients with advanced non-small-cell lung cancer ( NSCLC ) with an Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) of 2 . PATIENTS AND METHODS In a multicenter phase III r and omized trial , patients with advanced NSCLC , ECOG PS of 2 , any histology at first and later amended to nonsquamous only , no prior chemotherapy , and adequate organ function were r and omly assigned to P alone ( 500 mg/m(2 ) ) or CP ( area under the curve of 5 and 500 mg/m(2 ) , respectively ) administered every 3 weeks for a total of four cycles . The primary end point was overall survival ( OS ) . RESULTS A total of 205 eligible patients were enrolled from eight centers in Brazil and one in the United States from April 2008 to July 2011 . The response rates were 10.3 % for P and 23.8 % for CP ( P = .032 ) . In the intent-to-treat population , the median PFS was 2.8 months for P and 5.8 months for CP ( hazard ratio [ HR ] , 0.46 ; 95 % CI , 0.35 to 0.63 ; P < .001 ) , and the median OS was 5.3 months for P and 9.3 months for CP ( HR , 0.62 ; 95 % CI , 0.46 to 0.83 ; P = .001 ) . One-year survival rates were 21.9 % and 40.1 % , respectively . Similar results were seen when patients with squamous disease were excluded from the analysis . Anemia ( grade 3 , 3.9 % ; grade 4 , 11.7 % ) and neutropenia ( grade 3 , 1 % ; grade 4 , 6.8 % ) were more frequent with CP . There were four treatment-related deaths in the CP arm . CONCLUSION Combination chemotherapy with CP significantly improves survival in patients with advanced NSCLC and ECOG PS of 2
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV